The biotechnology company announced a complete recovery of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS immunotherapy.
- Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared, the company said.
- he 78-year-old patient received a total of 17 treatment cycles, and completed 12 months on the study.
- The company added that the trial has moved into Phase 2A, where Bria-OTS is being tested alongside an immune checkpoint inhibitor.
Shares of BriaCell Therapeutics Corp. (BCTX) surged more than 50% on Tuesday after the clinical-stage biotechnology company announced a ‘durable and sustained complete resolution’ of a lung metastasis in a patient with metastatic breast cancer treated with its Bria-OTS immunotherapy.
BriaCell said the patient was the first enrolled in its Bria-OTS clinical study and had previously failed multiple lines of treatment. Following four doses of Bria-OTS as a single-agent therapy, the lung metastasis completely disappeared. The response was first seen at two months and has since been confirmed at four, six, and now eleven months.
The 78-year-old patient received a total of 17 treatment cycles, completed 12 months on study, and continues to be monitored in survival follow-up. BriaCell noted that the Phase 1 dose-escalation portion of the trial has been completed successfully.
The company said the trial has now moved into Phase 2a, where Bria-OTS is being tested alongside an immune checkpoint inhibitor to potentially improve outcomes for patients with advanced breast cancer.
“These clinical findings reinforce our confidence in the therapeutic potential and safety of the Bria-OTS platform. Our team remains committed to advancing our novel therapeutic approach with the goal of making a meaningful difference for patients with metastatic breast cancer, particularly those with limited treatment options,” said William V. Williams, BriaCell’s President and CEO.
How Did Stocktwits Users React?
Retail sentiment on Stocktwits flipped to ‘extremely bullish’ from ‘neutral’, accompanied by ‘extremely high’ message volumes. BCTX was among the top trending tickers on the platform.
One bullish user expects the stock to touch $20 today. It is currently at $11.5.
Another user observed $11 as a key buying zone.
However, the stock has been under heavy selling pressure over the past year, declining more than 87%.
Read also: ALB Stock Garners Retail Attention As Lithium Bulls Return
For updates and corrections, email newsroom[at]stocktwits[dot]com.<
